參考資料
1.
Comparative activities of ciprofloxacin,
clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and
trovafloxacin against epidemiologically defined Acinetobacter baumannii
strains. Antimicrob Agents Chemother. 2000 Aug;44(8):2211-3.
2.
Comparison of minimal inhibitory and mutant
prevention drug concentrations of 4 fluoroquinolones against clinical isolates
of methicillin-susceptible and -resistant Staphylococcus aureus. Int J
Antimicrob Agents. 2004 Aug;24(2):161-7.
3.
Comparison of the bactericidal activity of
moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus
epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy. 2003
May;49(1-2):33-5.
4.
Community-Acquired Pneumonia Recovery in the
Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of
levofloxacin therapy. Clin Infect Dis. 2006 Jan 1;42(1):73-81. Epub 2005 Nov
22.
5.
Moxifloxacin versus levofloxacin for
treatment of acute rhinosinusitis: a retrospective database analysis of
treatment duration, outcomes, and charges. Curr Med Res Opin. 2006
Feb;22(2):327-33.
6.
Moxifloxacin versus levofloxacin against
acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir
Med. 2006 Sep;100(9):1504-11.
